Daiichi Sankyo says Sun Pharma to buy Indian unit Ranbaxy
TOKYO (Reuters) - Japan's Daiichi Sankyo Co Ltd (4568.T) said on Monday Sun Pharmaceutical Industries Ltd (SUN.NS) will buy its Indian unit Ranbaxy Laboratories Ltd (RANB.NS), creating the world's fifth-largest speciality generics company.
Daiichi Sankyo said in a statement that it agrees to vote its shares in Ranbaxy in favour of the acquisition through a share swap.
It said Ranbaxy shareholders will get 0.8 Sun Pharma shares for each Ranbaxy share. The merged company will also become the largest drug firm in India.
(Reporting by Dominic Lau; Editing by Stephen Coates)
- Tweet this
- Share this
- Digg this
- Masked gunmen slay family collecting body at Honduras morgue, kill 9
- U.S. military failed in rescue attempt for journalist Foley |
- Obama condemns killing of reporter, U.S. hits militants in Iraq |
- UK retail sales growth falls to eight-month low, public finances weak
- Israeli air strike kills three Hamas commanders in Gaza |